| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| G655110-1ml | 1ml | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $330.90 |
| Specifications & Purity | 10mM in DMSO |
|---|---|
| Storage Temp | Store at -80°C |
| Shipped In | Ice chest + Ice pads |
| Product Description | GNE-064 (compound 5) is a selective, orally active and highly soluble inhibitor of SMARCA4 , SMARCA2 and PBRM1 bromodomains 5. GNE-064 inhibits SMARCA4 with an IC 50 of 0.035 μM and inhibits SMARCA2 with an EC 50 of 0.10 μM. GNE-064 possess K d s with 0.01, 0.016, 0.018 and 0.049 μM for SMARCA4, SMARCA2, PBRM1 bromodomains 5 and PBRM1 bromodomains 2, repectively. GNE-064 can be used as a chemical probe for the research of agent synthesis In Vitro GNE-064 (0-0.5 μM; 1 h) inhibits SMARCA2 in ZsGreen-SMARCA2 BD-expressing U2OS cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: ZsGreen-SMARCA2 BD-expressing U2OS cells Concentration: 0-0.5 μM Incubation Time: 1 hour Result: Inhibited SMARCA2 in ZsGreen-SMARCA2 BD-expressing U2OS cells with an EC 50 of 0.1 μM. In Vivo GNE-064 (compound 5) (0.5 and 1.0 mg/kg; i.v. and p.o. once ) exibits ideal pharmacokinetics value in female CD-1 mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female CD-1 mice Dosage: 0.5 mg/kg (i.v.) and 1.0 mg/kg (p.o.) Administration: Intravenous injection and oral gavage; 0.5 mg/kg and 1.0 mg/kg once Result: Showed a low unbound plasma clearance with 16 mL/min/kg, a reasonable half-life of 1.1 h and good oral bioavailability of 59%. IC50& Target:IC50: 0.035 μM (SMARCA4) |
| Canonical SMILES | CC(N1[C@H](C)CN(C2=CC(C3=CC=CC=C3O)=NN=C2N)CC1)=O |
|---|---|
| Molecular Weight | 327.38 |
Enter Lot Number to search for COA:
